After three years of COVID-19, science has learned much about the disease and the virus that causes it, SARS-CoV-2. But in the bigger biological and clinical picture, there are still many unanswered questions, says Ligia Pinto, Ph.D. That’s what keeps her group, the Vaccine, Immunity, and Cancer Directorate at Frederick National Laboratory, working hard to hunt down answers.

NCI-MATCH aimed to determine whether certain cancer therapies could be used more broadly. If a medicine is effective against one type of cancer with a specific mutation, the trial asked, could it treat other cancers with the same mutation? After the eight-year trial, scientists say an answer is coming into view.

Early in the COVID-19 pandemic, before vaccines were available and while SARS-CoV-2 was wreaking havoc worldwide, Barry O’Keefe, Ph.D., and longtime collaborators in Brazil and Spain pooled their knowledge and resources to study cyanovirin-N (CV-N), a protein from cyanobacteria, photosynthetic bacteria commonly known as blue-green algae. O’Keefe had a hunch it could be developed to fight the spread of SARS-CoV-2.

The Werner H. Kirsten (WHK) program, a long-standing institution in Frederick, recently graduated its 32nd class. This unique internship opportunity continues to catapult many high school seniors on the path to STEM careers. Before the 2023 WHK student interns concluded their internships, WHK Program Manager Carrie Wagerman wanted to ensure they were recognized for their achievement in completing the rigorous program.

In the Natural Products Branch, projects demand a level of precision that makes Cinderella’s slipper look like child’s play. However, lab equipment isn’t always tailor-made for such uniqueness, sometimes requiring a little modification with special parts to get the job done. Sometimes those parts aren’t available. It rightly sounds like a headache, but Jason Evans and Matthew Harris say the group regularly pulls it off—at times, even in as little as a day.